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Abstract
Background: Observational studies are essential for assessing safety. The aims of this study were to evaluate
whether results of observational studies evaluating an intervention with safety outcome(s) registered at
ClinicalTrials.gov were published and, if not, whether they were available through posting on ClinicalTrials.gov or
the sponsor website.
Methods: We identified a cohort of observational studies with safety outcome(s) registered on ClinicalTrials.gov
after October 1, 2007, and completed between October 1, 2007, and December 31, 2011. We systematically
searched PubMed for a publication, as well as ClinicalTrials.gov and the sponsor website for results. The main
outcomes were the time to the first publication in journals and to the first public availability of the study results
(i.e. published or posted on ClinicalTrials.gov or the sponsor website). For all studies with results publicly available,
we evaluated the completeness of reporting (i.e. reported with the number of events per arm) of safety outcomes.
Results: We identified 489 studies; 334 (68 %) were partially or completely funded by industry. Results for only 189
(39 %, i.e. 65 % of the total target number of participants) were published at least 30 months after the study
completion. When searching other data sources, we obtained the results for 53 % (n = 158; i.e. 93 % of the total
target number of participants) of unpublished studies; 31 % (n = 94) were posted on ClinicalTrials.gov and 21 %
(n = 64) on the sponsor website. As compared with non-industry-funded studies, industry-funded study results were
less likely to be published but not less likely to be publicly available. Of the 242 studies with a primary outcome
recorded as a safety issue, all these outcomes were adequately reported in 86 % (114/133) when available in a
publication, 91 % (62/68) when available on ClinicalTrials.gov, and 80 % (33/41) when available on the sponsor
website.
Conclusions: Only 39 % of observational studies evaluating an intervention with safety outcome(s) registered at
ClinicalTrials.gov had their results published at least 30 months after study completion. The registration of these
observational studies allowed searching other sources (results posted at ClinicalTrials.gov and sponsor website) and
obtaining results for half of unpublished studies and 93 % of the total target number of participants.
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Background
Failure to provide access to research results is a key
source of wasted research [1]. The results for more than
50 % of clinical trials are never published, and publica-
tion is more likely for clinical trials with statistically sig-
nificant (positive) than negative results [2–6]. Lack of
the availability of research findings has serious conse-
quences; it affects the results of systematic reviews and
meta-analyses and distorts the evidence used for the
prioritization of research questions and clinical and pol-
icy decision-making [7–9]. In response to this waste, in
2005, the International Committee of Medical Editors
required the registration of all clinical trials, before study
inception, in a publicly accessible register such as Clini-
calTrials.gov [10, 11]. In 2007, the US Food and Drug
Administration Amendments Act also required the post-
ing of clinical trials results for all phase II to IV trials of
drugs, biologic treatments and devices having at least
one site in the United State at ClinicalTrials.gov no later
than 1 year after the date of final collection of data for
the pre-specified primary outcome [12]. In Europe, a
new law that will be implemented in 2016 will require
that all clinical trials be registered on a publicly access-
ible European Union clinical-trials register before they
can begin, with a summary of trial results posted within
a year after the end of the trial.
These policies have an important impact and allowed
increase research value. In fact, thanks to trials registra-
tion, unpublished studies are identified, and their results
could be made available through posting. However, regis-
tration is currently mandatory only for clinical trials.
Observational studies such as cohort and case–control
studies are important for assessing the intervention ef-
fect [13–16]. They are particularly useful designs when
randomized controlled trials (RCTs) are not feasible or
when assessing rare adverse events and long-term ef-
fectiveness. Such studies represent a large part of the
published literature and outnumber published RCTs
[17]. Nevertheless, prospective registration of observa-
tional studies is not currently requested [18]. Despite
not being mandatory, more than 35,000 observational
studies are registered at ClinicalTrials.gov.
Our hypothesis is that registration of observational
studies evaluating an intervention in ClinicalTrials.gov
is important to increase research value as it allows iden-
tifying unpublished studies and obtaining unpublished
results.
The main objectives of this study were (1) to evaluate
whether results of observational studies evaluating an
intervention with safety outcome(s) registered at Clini-
calTrials.gov were published and, if not, whether they
were available through posting on ClinicalTrials.gov or
the sponsor website; (2) to evaluate and compare the
time to publication and to public availability of results
after searching other sources by study funding source;
and (3) to evaluate the completeness of reporting of the
outcomes designated as safety issues.
Methods
We identified a cohort of observational studies evaluat-
ing an intervention with safety outcome(s) registered at
ClinicalTrials.gov.
Search for relevant studies
We searched ClinicalTrials.gov on April 14, 2014, by
using “completed” for recruitment, “observational stud-
ies” for study type, and date of first registration between
October 1, 2007, and December 31, 2011, and “has an
outcome measure designated as a safety issue” in the
safety issue field of ClinicalTrials.gov. We chose October
2007 because modifications were made at this time to
the design-specific data elements used for registering ob-
servational studies on ClinicalTrials.gov. These changes
were strongly influenced by protocol-related items in the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement [13].
Observational studies are defined by ClinicalTrials.gov
as studies where “investigators assess health outcomes in
groups of participants according to a protocol or research
plan. Participants may receive interventions, which can
include medical products, such as drugs or devices, or
procedures as part of their routine medical care, but par-
ticipants are not assigned to specific interventions by the
investigator (as in a clinical trial https://clinicaltrials.-
gov/ct2/about-studies/glossary#O).”
Identification of relevant observational studies
Among the studies retrieved, we identified all observa-
tional prospective studies assessing interventions that
had a primary completion date (i.e. the date when the
final patient was examined or received an intervention
for the purposes of final collection of data for the pri-
mary outcome) between October 1, 2007, and December
31, 2011. We defined interventions as all pharmacologic
and non-pharmacologic treatments (pharmaceutical drugs,
surgery, education, rehabilitation, etc.) aimed at improving
the participants’ health. We chose this time period to be
able to investigate public availability (i.e. at least 24 months
after the study primary completion). We excluded studies
with a primary completion date after December 2011,
studies assessing genetics, predictors, or risk factors; not
assessing interventions, pharmacodynamics, and pharma-
cokinetics of drugs; phase 0, I, II, I/II and II/III studies;
studies with healthy volunteers, and retrospective and ran-
domized studies. We also excluded studies for which the
primary completion date was not reported at Clinical-
Trials.gov. The selection process was performed by one
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researcher, and all records included were independently
verified by a second researcher.
Extraction of data from ClinicalTrials.gov
We downloaded from ClinicalTrials.gov the following
data concerning the characteristics of the studies: clinical
trial number (NCT), title, study design (defined with the
observational model: cohort, case–control, case-only,
case crossover or other; and time perspective: prospect-
ive, cross-sectional or other), enrollment (i.e. sample
size), first received date, primary completion date, results
first received date, condition and intervention under
study, outcome measures, locations of recruitment and
funding source. The funding source was classified at Clini-
calTrials.gov as “NIH” (National Institutes of Health), “US
federal”, “industry”, and other non-industry organizations
(universities, hospitals, foundations, and other government
and other non-industry organizations). We secondarily cat-
egorized funding sources as non-industry (i.e. funded by
NIH, US federal, other non-industry organizations) or in-
dustry (i.e. partially or totally funded by industry).
One researcher classified the following information from
the full ClinicalTrials.gov record: medical field, type of
intervention (drug, device, procedure/surgery, other), loca-
tion of recruitment (Europe, North America, South Amer-
ica, Africa, Asia, Oceania) and study purpose as safety,
efficacy or both. As a quality assurance procedure, a sec-
ond researcher independently verified 50 % of the data.
Publication of study results in journals
For each observational study identified, we systematically
searched for a publication reporting the study results
(search date June 2014). First, we examined the “publica-
tion” field at ClinicalTrials.gov to search for a citation
for an article that described the study results. If no cit-
ation was reported, we searched MEDLINE via PubMed
by using the ClinicalTrials.gov identification number
(NCT). If no publication was identified, we searched
MEDLINE via PubMed by using keywords for the inter-
vention under study and the condition. A researcher
screened all citations retrieved up to the primary com-
pletion date registered at ClinicalTrials.gov and selected
all citations corresponding to the selected study. A sec-
ond researcher independently performed the search on
PubMed for all the studies for which no publication was
identified; any discrepancies were discussed until obtain-
ing consensus.
Finally, if no publication was identified, we contacted
the sponsor or the principal investigator. We searched in
the “additional information” field of ClinicalTrials.gov
for a link to the sponsor website for contacting the
sponsor. If no link was available, we recorded the
principal investigator’s name from the “contacts and
locations” fields of ClinicalTrials.gov and searched
PubMed and Google to identify their email address. The
email reminded the recipient of the study NCT number
and inquired about the study publication, presentation at
a congress, and plans for future publication (Additional
file 1: Appendix 1). We systematically sent two reminders.
If no answer was received, the study findings were consid-
ered unpublished. When the study results were reported
as an abstract or poster presented at a scientific meeting,
we considered that the results were not available. In fact,
previous evidence showed that the quality of abstracts
presented at meetings is suboptimal, frequently including
results that are not the final results [19, 20].
To determine whether the publication(s) corresponded
to the registered observational study, we retrieved the
full-text article for all citations selected and assessed
from the abstract and the full text, if needed, whether a
combination of information, including description of in-
terventions and conditions, population, location, respon-
sible party, number of participants, primary outcome
measures, and primary funding sponsor partly or com-
pletely matched the information at ClinicalTrials.gov.
We only selected articles that reported the results of the
study. All cases were assessed by a second independ-
ent researcher, and disagreements were resolved by
consensus.
If the publication highlighted that the study did not
actually fulfill the inclusion criteria, while it was impos-
sible to detect it from ClinicalTrials.gov record, the stud-
ies were still included in the analysis and considered as
published to avoid bias. This occurred for eight studies
(randomized n = 6; retrospective n = 1; phase 0/I/II n = 1).
Search of results posted on ClinicalTrials.gov and the
sponsor website
For each observational study identified, we assessed
whether unpublished results were publicly available from
other sources. For this purpose, (1) we searched whether
results were posted at ClinicalTrials.gov and (2) systemat-
ically searched the sponsor website to identify whether the
results were available. For this, we searched Clinical-
Trials.gov for a link to the sponsor website. If no link was
available, we searched Google using the sponsor name to
identify the sponsor website. Then, we searched the web-
site for a section dedicated to access to study results and
used the study NCT number to find the study results.
Main outcomes
The main outcomes were the time to the first publication
in journals, and the time to the first public availability of
the study results.
The time to the first publication in journals was the time
(in months) that elapsed between the primary completion
date of the study and the publication. The study primary
completion date was obtained from ClinicalTrials.gov.
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The publication date was the first date an article was made
available online ahead of print (i.e. epub date indexed on
PubMed) or published in a paper-printed version.
The time to the first public availability of the study
results was the time (in months) between the primary
completion of the study and the first public availability
of the study results by publication or posting on Clini-
calTrials.gov or the sponsor website. When results were
available in different sources, we used the first date.
Secondary outcomes were the proportion of study
results publicly available (via publication or posting on
ClinicalTrials.gov or the sponsor website) at 12 and
24 months after primary completion.
Completeness of reporting of outcomes designated as
safety issues
For all studies with results publicly available (via publi-
cation or posting on ClinicalTrials.gov or the sponsor
website), we evaluated the completeness of reporting of
all primary outcome measure(s) designated as a “safety
issue” and when not available, all secondary outcome
measure(s) designated as a safety issue as recorded from
ClinicalTrials.gov. Then, for each outcome recorded, we
systematically searched in the report available (i.e. publi-
cation, and for unpublished studies, results posted on
ClinicalTrials.gov or the sponsor website) whether the
results were adequately reported (i.e. reported with the
number of events per arm), partially reported (i.e. re-
ported with the number of events pooled or only men-
tioned), or not reported. When several publications were
available, we selected the publication with the results
more completely reported.
For all studies with results publicly available, we deter-
mined the proportion of studies with all primary out-
comes designated as safety issues adequately reported
and when not available, the proportion of studies with
all secondary outcomes adequately reported.
For this analysis, we excluded studies when the results
were not published or available in English.
Statistical analysis
Quantitative variables are described with median (quartile
1–3; Q1–Q3) and qualitative variables with number and
percentages. For each outcome, we assessed Kaplan-Meier
estimates of the cumulative incidence of studies (with
95 % confidence interval (CI)) at 12 and 24 months. All
studies without results available in the different sources
were censored on June 1, 2014 (i.e. search date). Cumula-
tive incidence curves estimated by Kaplan–Meier methods
are displayed globally and by funding source (partially or
completely industry-funded; non-industry-funded). Uni-
variate and multivariate Cox proportional hazards regres-
sion analyses were used to calculate adjusted hazard ratios
(HRs) by funding source (with 95 % CIs and P values from
Search strategy
n = 1243 citations
Assessment of the study record at Clinicaltrial.gov
n = 737
Exclusion using ClinicalTrials.gov filters
n = 506
Studies with primary completion date 
after12.31.11
Retrospectives studies 
Phase 0, 1, or 2 studies 
Studies without primary completion date 
reported 





n = 24 
n = 57
Randomized controlled trials
Studies not assessing a medical Intervention
Studies evaluating a genetic, predictor or risk 
factors, or pharmacodynamics and
pharmacokinetics of drugs
Retrospectives studies
Phase 0, 1, or 2 studies
Studies with healthy volunteers










Studies included in the analysis
n = 489
Fig. 1 Selection of observational studies
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Wald test). The following confounding variables were
entered in the multivariate Cox model: type of inter-
vention (drug, device, procedure/surgery, or other), loca-
tion recruitment (Africa/Asia/South America or Europe/
Australia/North America), objective of the study (safety or
both efficacy and safety, or only efficacy), sample size and
registration period (before the start date of the study/be-
tween the start date of the study and the primary study
completion/after the primary study completion date).
Statistical analysis involved use of SAS v9.4 (SAS
Inst. Inc., Cary, NC) and R software (v3.1.2) (http://www.
R-project.org, the R Foundation for Statistical Computing,
Vienna, Austria).
Results
Study selection and characteristics
From the 1,243 citations screened, 489 studies were
selected (Fig. 1). The characteristics of the selected studies
are shown in Table 1. Only about one-quarter of the stud-
ies were registered before the start date of the study; 30 %
were registered after the study primary completion date.
Overall, 333 studies (68 %) were conducted in high-income
countries, 111 (23 %) with at least one site in North Amer-
ica, and 68 % (n = 334) were partially or completely funded
by industry. The median (Q1–Q3) sample size was 300.0
(75.0–1045.0); 507.0 (131.0–1794.0) for studies with in-
dustry funding and 80.0 (32–219.0) for those with non-
industry funding. The cumulative target enrollment for all
studies was 1,214,218 participants. The study objective in
72 % (n = 351) of studies was to assess safety.
Publication of study results
The median time between the study primary completion
date and our search was 49.0 (Q1–Q3, 41.0–62.0) months;
for all studies, at least 30 months had elapsed since the
study primary completion date. Among the 489 studies,
Table 1 Characteristics of selected studies (n = 489) by funding: industry or non-industry




Total (n = 489)
Registration Before the start date of the study 69 (20.7) 43 (27.7) 112 (22.9)
Between the start date of the study
and study primary completion date
174 (52.1) 58 (37.4) 232 (47.4)
After the study primary completion date 91 (27.2) 54 (34.8) 145 (29.7)
Medical field Cardiovascular 51 (15.3) 27 (17.4) 78 (16.0)
Endocrinology 61 (18.3) 4 (2.6) 65 (13.3)
Infectious diseases 46 (13.8) 16 (10.3) 62 (12.7)
Urology/gynecology 30 (9.0) 13 (8.4) 43 (8.8)
Rheumatology 23 (6.9) 2 (1.3) 25 (5.1)
Bronchopulmonary 20 (6.0) 9 (5.8) 29 (5.9)
Neurology 18 (5.4) 6 (3.9) 24 (4.9)
Oncology 12 (3.6) 10 (6.5) 22 (4.9)
Gastroenterology 11 (3.3) 19 (12.3) 30 (6.1)
Ophthalmology 10 (3.0) 9 (5.8) 19 (3.9)
Psychiatry 10 (3.0) 2 (1.3) 12 (2.5)
Other 42 (12.6) 38 (24.5) 80 (16.4)
Location Africa/Asia/South America 114 (34.1) 42 (27.1) 156 (31.9)
Europe/Australia/North America 220 (65.9) 113 (72.9) 333 (68.1)
Intervention Drug 278 (83.2) 52 (33.5) 330 (67.5)
Device 43 (12.9) 45 (29.0) 88 (18.0)
Procedure/surgery 9 (2.7) 54 (34.8) 63 (12.9)
Other 4 (1.2) 4 (2.6) 8 (1.6)
Sample size ≤100 68 (20.4) 94 (60.6) 162 (33.1)
100–500 95 (28.4) 40 (25.8) 135 (27.6)
>500 171 (51.2) 21 (13.5) 192 (39.3)
Study objective Safety or both safety and efficacy 279 (83.5) 72 (46.5) 351 (71.8)
Efficacy 55 (16.5) 83 (53.5) 138 (28.2)
Data are presented as number (%)
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we identified a publication via the citation reported at
ClinicalTrials.gov for 75 and via a systematic search of
PubMed for 99. For the 314 remaining studies without a
publication identified, we obtained an email address and
contacted the sponsor/principal investigator of 241 stud-
ies, of which 52 responded and 15 provided an article
(Additional file 1: Appendix 2).
Overall, results of only 189 (39 %) studies were pub-
lished at least 30 months after study primary comple-
tion, corresponding to a cumulative target of enrollment
of 785,437 participants (65 % of the total target number
of participants). The global cumulative percentage of
studies with results published over time and stratified by
funding source are in Fig. 2. The cumulative percentage
of observational studies with results published 12 months
after primary completion was 8.2 % (95 % CI, 5.7–10.6):
4.8 % (95 % CI, 2.5–7.1) of industry-funded studies and
15.5 % (9.8–21.2) of non-industry-funded studies. At
24 months, 21.3 % (17.6–24.9) of studies were published:
13.2 % (9.5–16.8) of industry-funded studies and 38.7 %
(31.0–46.4) of non-industry-funded studies. After adjust-
ing for confounding variables (i.e. type of intervention,
location recruitment, objective of the study, sample size
and registration period), industry-funded study results
Fig. 2 Probability of first publication in journals by funding source for published articles indexed in PubMed for a) the whole sample of 489
observational studies and b) stratified by funding source
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were less likely to be published than non-industry
funded studies (adjusted HR, 0.39; 95 % CI, 0.27–0.56;
P <0.0001).
Posting of study results on ClinicalTrials.gov and on the
sponsor website
When searching the results section of ClinicalTrials.gov,
we obtained the results for 31 % (n = 94) of our unpub-
lished studies (i.e. 147,593 cumulative target participants).
When searching sponsor websites, we obtained the results
for 64 (21 %) of unpublished studies (i.e. 195,291 cumula-
tive target participants), of which 39 could be obtained
through a link to the sponsor website available in Clinical-
Trials.gov. All study results obtained from sponsor web-
sites were sponsored by Bayer (n = 16), GSK (n = 12), or
Novo Nordisk (n = 36).
Overall public availability of study results
Figure 3 summarizes the public availability of results of
the selected studies in terms of publication or posting
on ClinicalTrials.gov or the sponsor website. Overall,
347 studies (71 %) had results publicly available at least
30 months after study primary completion, correspond-
ing to a cumulative target of enrollment of 1,128,321
participants (i.e. 93 % of the total target number of par-
ticipants). The median (Q1–Q3) sample size of studies
with publication available was 165 (60–882), studies with
unpublished data available through ClinicalTrials.gov,
503 (154–1307) studies with unpublished data available
through the sponsor website 1001 (393–2366), and stud-
ies with no results publicly available 130 (50–556).
The cumulative proportion of studies with results pub-
licly available over time overall and stratified by funding
source is shown in Fig. 4. Overall, the cumulative per-
centage of studies with results publicly available was
27.0 (23.1–30.9) at 12 months and 51.7 (47.3–56.2) at
24 months; the proportion for industry- and non-
industry-funded studies was 30.8 % (25.9–35.8) versus
18.7 % (12.6–24.8) at 12 months and 55.4 % (50.1–60.7)
versus 43.9 % (36.0–51.7) at 24 months. After adjusting
for confounding variables, the probability of having
results publicly available did not differ between industry-
funded and non-industry-funded studies (adjusted HR,
1.16; 95 % CI, 0.88–1.52; P = 0.30). Additional file 1:
Appendix 3 reports the availability of the study results
according to the date of registration (before the start of
the study, between the start and the study completion,
after the study completion). Overall, 43 % of the studies
that were registered after the study primary completion
date were published, 33 % were not published but had
their data available in other sources, and 23 % had no
data available.
Completeness of reporting (Table 2)
Of the 347 studies with results publicly available, 243
reported at least one primary outcome measure desig-
nated as a “safety issue”. We evaluated the completeness
of reporting of 242 studies (one excluded because not
published in English): all these outcomes were ad-
equately reported in 86 % (114/133) when available in a
publication, 91 % (62/68) when available on Clinical-
Trials.gov, and 80 % (33/41) when available on the spon-
sor website. Of the 96 studies that did not have a
primary outcome measure designated as a “safety issue”,
66 (69 %) adequately reported all secondary outcomes
designated as a safety issue; 60 % when available in a
publication, 92 % when available on ClinicalTrials.gov,
and 61 % when available on the sponsor website.
Discussion
We evaluated the public availability of study results in a
cohort of 481 observational studies evaluating an inter-
vention with safety outcome(s) registered at Clinical-
Trials.gov and completed for more than 30 months. Only
39 % (n = 189) had results published, corresponding to
65 % of the total target number of participants. The
Fig. 3 Availability of study reports at least 30 months after study completion
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cumulative percentage of studies with results published at
12 and 24 months after primary completion were 8.2 %
(95 % CI, 5.7–10.6) and 21.3 % (17.6–24.9), respectively.
However, when searching other data sources (results
posted on ClinicalTrials.gov and sponsor websites), we
obtained the results for about half of the studies with
unpublished results (n = 158, 53 %) corresponding to 93 %
of the total target number of participants. Further, the
median sample size of unpublished results posted on
ClinicalTrials.gov and sponsor websites was high.
To our knowledge, this is the first large study evaluat-
ing the public availability of the results of observational
studies registered at ClinicalTrials.gov in terms of publi-
cation or posting on ClinicalTrials.gov or the sponsor’s
website. Most evidence of the lack of availability of re-
search results has focused on the publication of clinical
trials and the posting of results on ClinicalTrials.gov
[5, 6, 21–24]. Large cohorts of registered clinical trials
showed that the results of only 46–63 % are published
[21, 23]. In the field of diagnostic studies, results for
54 % of studies completed for at least 18 months were
published [25].
Our study has several important implications; they
clearly illustrate the need for a change in policy with a
Fig. 4 Overall public availability of study results (publication available or results posted on ClinicalTrials.gov or the sponsor website) and by
funding source
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request to also prospectively register observational stud-
ies. In many situations, observational studies are the
only data available because RCTs are not appropriate or
feasible. The number of published meta-analyses includ-
ing observational studies in health has increased sub-
stantially and these meta-analyses could be used to
inform clinical decision-making and public health policy
[18, 26]. Registration of observational studies is debated,
as shown by recent editorials published in major medical
journals [17, 27–32]. However, much of the rationale for
the prospective registration of clinical trials [18, 33] also
applies to the registration of observational studies. Al-
though registration at ClinicalTrials.gov does not guar-
antee that trial results will be published in a timely
manner [22, 34–36], it allows knowing the existence of
the study, searching for unpublished data, exploring
publication bias, outcome reporting bias, and fidelity to
the protocol [37, 38].
Our results also highlight the need to reconsider
the strategy used to identify research findings. In fact,
searching the results section at ClinicalTrials.gov as
well as the sponsor website increased by two-fold the
number of studies with results available and allowed
access to the data of 93 % of the total target number
of participants. It is consequently very important that
systematic reviewers search for these data in trials regis-
tries and the sponsors websites. Previous studies com-
paring the results posted and published for clinical trials
showed that results are more completely reported in
registries than in publications [21, 23] and that discrepan-
cies between the ClinicalTrials.gov results database and
matching publications are common [38]. However, it is
unclear which source is more accurate [38].
Publication of research findings in peer-reviewed jour-
nals is considered essential for disseminating research
results. However, the publication process is long, com-
plicated and supposes an important investment from the
sponsor and investigator. Lack of or delayed publication
could be related to the lack of incentives to disseminate
negative results, time constraints, limited resources,
changing interests, or difficulties and failure to have the
results published [34]. The sponsor may prefer posting
results on a website than investing in publication in a
peer-reviewed journal. However, we question why spon-
sors post results on their website and not on Clinical-
Trials.gov. In fact, ClinicalTrials.gov performs a quality
control, which is not the case with the sponsor website.
Finally, ClinicalTrials.gov offers researchers the oppor-
tunity to provide access to their data if they decide not
to publish them in a peer-reviewed journal. For clinical
trials, the posting of results is a requirement. The World
Health Organization is calling for a strict timeline for
public disclosure of clinical trial results and published a
new Statement on the Public Disclosure of Clinical Trial
Results, which specifies that study results be reported at
least 30 months after a study is completed. This require-
ment should also be extended to observational studies.
Our study has some potential limitations. First, as
registration of observational studies is not mandatory,
we could explore the public availability of the trial
results only for observational studies registered at Clini-
calTrials.gov. However, the publication rate and public
availability of results is not likely to be higher for obser-
vational studies that were not registered. Second, our
search was performed only in Medline via PubMed and
we may have missed some publications. However,
Medline is the largest database of biomedical journals
and is the source that nearly all physicians and policy-
makers use to access clinical trial findings. Further, a re-
cent study showed that searching Embase has a modest
Table 2 Completeness of reporting of primary outcomes and secondary outcomes designated as a “safety issue”
Published articlesa Results not published but
posted on ClinicalTrials.gov
Results not published but
posted on the sponsor website
Total
Completeness of reporting of primary outcome(s)
designated as a safety issue
n = 133 n = 68 n = 41 n = 242
All outcomes adequately reported 114 (85.7) 62 (91.2) 33 (80.5) 209 (86.4)
At least one outcome partially reported or
not reported
9 (6.8) 2 (2.9) 6 (14.6) 17 (7.0)
All outcomes not reported 10 (7.5) 4 (5.9) 2 (4.9) 16 (6.6)
Completeness of reporting of secondary
outcome(s) designated as a safety issue for trials
with no primary outcomes designated as a
safety issue
n = 47 n = 26 n = 23 n = 96
All outcomes adequately reported 28 (59.6) 24 (92.4) 14 (60.9) 66 (68.7)
At least one outcome partially reported or not reported 10 (21.3) 1 (3.8) 8 (34.8) 19 (19.8)
No outcome reported 9 (19.1) 1 (3.8) 1 (4.3) 11 (11.5)
Data are presented as number (%)
aOne missing value
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impact on the results of systematic reviews [39] and
most studies evaluating RCT publication did not search
Embase [21, 34]. Additionally, we systematically contac-
ted the sponsor or investigator to check whether the
study was published. Finally, we used the data recorded
at ClinicalTrials.gov, but this information is not always
accurate, and ClinicalTrials.gov added a database of
summary results allowing for reporting results of obser-
vational studies according to the STROBE statement
only in September 2008.
Conclusion
In conclusion, about 39 % of observational studies evalu-
ating an intervention with a safety outcome and regis-
tered at ClinicalTrials.gov had their results published.
Searching for unpublished data allowed for access to
more than two-thirds of the study results and 93 % of
the total target number of participants. Given the poten-
tial important benefit of requesting the registration of
observational studies, this practice should be required by
research regulations.
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